Our US-Based Support team is available to help. Contact Us Now
Phone: 800-441-1045 | Email: support@kidneyhood.org
Albutrix was developed to address limitations that previous-generation keto acid analogs had not solved. Most alternatives were formulated decades ago, before current understanding of calcium supplementation risks, magnesium's role in CKD survival outcomes, and the importance of glycemic safety for the large population of diabetic kidney patients.
Every differentiation below is based on formulation science, current guideline compliance, or documented clinical outcomes — not marketing claims.
✔ Patent pending magnesium keto analogs and magnesium/calcium blends to comply with 2020 guidance to reduce risks for stage 3 and 4 patients.
✔ Lowest nitrogen content of any protein food or supplement for kidney patients.
✔ Lowest calcium content of any keto analog protein food or supplement.
✔ Albutrix also acts as a phosphorus binder.
✔ Albutrix is the only keto analog that is part of an integrated strategy to lower workload on your kidneys.
✔Albutrix is the only keto analog that allows you to choose options based on your current blood tests so you always have access to the right keto acid or protein food.
✔ Albutrix is low glycemic and diabetic friendly; other options list high glycemic ingredients like sugars/starches like maltodextrin as the main ingredient.
✔ Albutrix is the only keto analog to follow guidelines from the National Kidney Foundation, American Academy of Nutrition and Dietetics, and guidance from over 20 countries when combined with the Stopping Kidney Disease Diet and Microtrix.
✔ Albutrix is the only keto acid for kidney patients that lists nitrogen, calcium, magnesium, and dietary protein equivalents on the label so patients/caregivers can plan their diets accurately.
✔ Albutrix allows patients to consume more calories and dietary protein each day with the same or lower nitrogen load as other options.
The Clinical Standard We Hold Ourselves to
The Kidneyhood program has been studied in human CKD patients using the same clinical endpoints the FDA requires for kidney disease drug approval — eGFR, BUN, and creatinine. The pilot study used informed consent, HIPAA-compliant data collection, and standard statistical methodology. A statistically significant dose-response relationship between achieved BUN level and eGFR improvement (p = 0.002) was identified.
We recognize that a new integrated approach must earn its evidence. We welcome that standard.
US Patent 11,253,496 | EU Patent 3,799,724 | New clinical studies underway 2026 Manufactured in FDA-registered US facilities | Lot-tested before every release
US-BASED SUPPORT
Still Have Questions?
FDA-REGISTERED & USA MADE